基因編輯相關的合作與授權協議（2016-2026）

基因編輯領域交易的權威指標

基因編輯領域的合作是由先進的平台技術和快速創新所驅動的，合約結構體現了專有工具、智慧財產權和下一代治療能力的取得。

本報告對 410 項基因編輯合作及授權協議進行了全面系統的分析，清晰且有實證支持地闡述了整個市場夥伴關係的設計、談判和執行方式。

清楚了解市場標準

本報告將使您對基因編輯交易的實際運作方式有清晰的了解，使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑和忠誠度結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解合約條款如何因平台類型、應用程式和合作夥伴概況而異。
• 支持基於證據的評估和合約結構確定。
• 內部討論應基於實際交易數據，而不是假設。
• 了解大型公司如何處理交易
• 在高度創新、智慧財產權主導的環境中，可視化合作夥伴行為和重複交易結構。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，從而可以詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解基因編輯夥伴關係中價值、風險和控制權的分配方式至關重要，尤其是在平台准入、智慧財產權定位和新興治療應用等領域。
• 專為實際業務拓展和策略制定而設計。

本報告主要廣泛用於以下用途：

• 平台及先進技術交易的結構化與基準測試
• 在清晰的市場環境下準備談判
• 許可、聯合開發和技術合作的評估
• 支援穩健且引人注目的數據驅動型內部策略
• 內容
• 410項基因編輯合作及授權協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 一個可全文搜尋的合約目錄（按公司、平台和應用程式分類）。
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 分析交易趨勢、重大交易和活躍的交易商。
• 基因編輯領域交易中可靠的、基於證據的參考資料。
• 本報告結合全面的交易報告和合約層面的深入分析，為如何在基因編輯領域建立、談判和評估夥伴關係提供了可靠的、基於證據的參考資料。

目錄

執行摘要

第1章：引言

第2章：基因編輯交易趨勢

• 介紹
• 基因編輯領域的長期協議
• 基因編輯交易中最活躍的相關人員
• 基因編輯交易（按交易類型）
• 基因編輯交易（按治療領域分類）
• 基因編輯交易（按行業分類）
• 基因編輯交易的條款與條件

第3章：基因編輯領域的主要交易

• 介紹
• 高價值的基因編輯相關暢銷交易

第4章：基因編輯交易中最活躍的相關人員

• 介紹
• 基因編輯交易中最活躍的相關人員
• 參與最活躍基因編輯交易的公司簡介

第5章 基因編輯合約交易目錄

• 介紹
• 基因編輯合約交易目錄

第6章 依技術類型分類的基因編輯交易

• 特價優惠列表
• 交易清單 - AZ 基因編輯交易（按公司）
• 交易清單 - 基因編輯交易（按交易類型）
• 交易清單 - 基因編輯交易（按治療領域分類）
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for gene editing dealmaking

Gene editing partnering is driven by advanced platform technologies and rapid innovation, with deal structures reflecting access to proprietary tools, intellectual property, and next-generation therapeutic capabilities.

This report provides a comprehensive and structured analysis of 410 gene editing collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how gene editing deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by platform type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly innovative and IP-driven landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within gene editing partnerships, particularly in areas involving platform access, IP positioning, and emerging therapeutic applications.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark platform and advanced technology transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing, co-development, and technology partnerships
• Support internal strategy with robust, defensible data
• What's included
• 410 gene editing collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, platform, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for gene editing dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how gene editing partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

• 2.1. Introduction
• 2.2. Gene editing deals over the years
• 2.3. Most active gene editing dealmakers
• 2.4. Gene editing deals by deal type
• 2.5. Gene editing deals by therapy area
• 2.6. Gene editing deals by industry sector
• 2.7. Deal terms for gene editing deals
  • 2.7.1 Gene editing deals headline values
  • 2.7.2 Gene editing deal upfront payments
  • 2.7.3 Gene editing deal milestone payments
  • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

• 3.1. Introduction
• 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

• 4.1. Introduction
• 4.2. Most active gene editing dealmakers
• 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

• Deal directory
• Deal directory - Gene editing deals by company A-Z
• Deal directory - Gene editing deals by deal type
• Deal directory - Gene editing deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene editing deals since 2016
• Figure 2: Active gene editing dealmaking activity since 2016
• Figure 3: Gene editing deals by deal type since 2016
• Figure 4: Gene editing deals by therapy area since 2016
• Figure 5: Gene editing deals by industry sector since 2016
• Figure 6: Gene editing deals with a headline value
• Figure 7: Gene editing deals with an upfront value
• Figure 8: Gene editing deals with a milestone value
• Figure 9: Gene editing deals with a royalty rate value
• Figure 10: Top gene editing deals by value since 2016
• Figure 11: Most active gene editing dealmakers since 2016
• Figure 12: Gene editing deals by technology type since 2016